**Core Concept**
The concomitant use of valproic acid and lamotrigine is a pharmacokinetic interaction that affects the metabolism and clearance of one or both drugs. This interaction is due to the inhibition of glucuronidation, a phase II metabolic pathway, by valproic acid.

**Why the Correct Answer is Right**
Valproic acid is a potent inhibitor of the enzyme UDP-glucuronyltransferase (UGT), which is responsible for the glucuronidation of lamotrigine. When valproic acid is co-administered with lamotrigine, it reduces the activity of UGT, leading to decreased glucuronidation of lamotrigine. As a result, the plasma concentrations of lamotrigine increase, increasing the risk of adverse effects such as Stevens-Johnson syndrome and toxic epidermal necrolysis. This interaction is more pronounced in individuals with genetic polymorphisms in the UGT1A4 gene, which codes for the enzyme responsible for lamotrigine glucuronidation.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not mentioned in the context of the interaction between valproic acid and lamotrigine.
* **Option B:** While liver enzyme induction can be a concern with certain medications, it is not relevant to the interaction between valproic acid and lamotrigine.
* **Option C:** This option is not a known adverse effect of the concomitant use of valproic acid and lamotrigine.

**Clinical Pearl / High-Yield Fact**
When prescribing lamotrigine to patients taking valproic acid, it is essential to monitor plasma lamotrigine concentrations and adjust the dose accordingly to minimize the risk of adverse effects.

**Correct Answer: C. Stevens-Johnson syndrome and toxic epidermal necrolysis.**